Table 1.

Cohort description and loss to follow up analysis for patients in the Kenyan Wilms Tumor Registry.

	Overall		Loss to Follow Up (LTFU) Analysis
	Statistic (n)	95% CI	Not LTFU	LTFU	p*
Male, %	53.4 (133)	44.5 – 62.1	49.4	59.3	0.291†
NHIF‡ Participant, %	53.7 (123)	44.4 – 62.7	53.9	53.2	1.000†
Age In Months, mean	41 (133)	36.7 – 45.3	40.0	42.4	0.601§
Months of Symptoms Prior to Diagnosis, mean	3.1 (66)	2.2 – 3.9	2.97	3.2	0.800§
Days From Presentation To Diagnosis, mean	15.5 (133)	9.6 – 21.4	20.8	7.8	0.033§
Days From Presentation To First Therapeutic Intervention, mean	41.2 (118)	27.6 – 54.8	41.4	41.0	0.973§
Days of Follow-Up, mean	263.3 (133)	210.4 – 316.2	270.4	253.0	0.750§
Number Mobile Numbers, mean	1.3 (132)	1.2 – 1.4	1.3	1.3	0.910§
Patient HIV** positive, %	2.4 (42)	00.0 – 12.6	3.7	0.0	1.000†
Parent HIV positive, %	7.4 (27)	00.9 – 24.2	5.9	10.0	1.000†
Up Front Resection††, %	27.6 (127)	20.0 – 36.1	21.6	35.9	0.107†
Preoperative Chemotherapy††, %	74.3 (82)	63.6 – 83.4	64.7	90.3	0.010†
Resection††, %	69.9 (133)	61.4 – 77.6	58.2	87.0	0.080†
Postoperative Chemotherapy††, %	51.8 (83)	40.6 – 62.9	41.5	61.9	0.002†
Radiotherapy††, %	16.8 (131)	10.8 – 24.3	12.7	23.1	0.153†
Completed all Therapy, %	24.8 (133)	17.7 – 33.0	13.9	40.7	0.001†
Currently Receving Treatment, %	18.8 (133)	12.5 – 26.5	31.7	0.0	< 0.001†
Stage Estimates, % (n = 125)
I	3.2 (4)		2.6	4.1
II	42.4 (53)		47.4	34.7
III	36 (45)		26.3	51.0
IV	16.8 (21)		21.1	10.2
V	1.6 (2)		2.6	0.0	0.034†
Laterality % (n = 131)
Right	48.1 (63)		56.4	41.5
Left	50.4 (66)		41.0	58.5
Bilateral Synchronous	1.5 (2)		2.6	0.0	0.085†

^*p compares NOT lost to follow up to lost to follow up.

^†Fishers Exact

^‡National Hospital Insurance Fund

^§T-Test

^**Human Immunodeficiency Virus

^††Patient completed the given therapy